The effect of antihistamines on seizures induced by increasing-current electroshocks: Ketotifen, but not olopatadine, promotes the seizures in infant rats

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 5, 2012, Pages 693-697

  Yamada, Koji ^a   Takizawa, Fumitake ^a   Tamura, Tadafumi ^a   Kanda, Tomoyuki ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Increasing current electroshock; Infant rat; Ketotifen; Olopatadine; Seizure

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; FEXOFENADINE; KETOTIFEN FUMARATE; OLOPATADINE;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; ELECTRIC CURRENT; ELECTRIC SHOCK; MALE; NEUROTRANSMISSION; NONHUMAN; RAT; SEIZURE; SEXUAL MATURATION;

AGE FACTORS; ANIMALS; ANTI-ALLERGIC AGENTS; BRAIN; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DIBENZOXEPINS; ELECTROSHOCK; EPILEPSY; GABA ANTAGONISTS; HISTAMINE H1 ANTAGONISTS; KETOTIFEN; MALE; PENTYLENETETRAZOLE; RATS; RATS, WISTAR; SEIZURES; TERFENADINE;

EID: 84861205620     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.693     Document Type: Article

References (33)

1. McDonald K, Trick L, Boyle J. Sedation and antihistamines: an update. Review of inter-drug differences using proportional impairment ratios. Hum. Psychopharmacol., 23, 555-570 (2008).
2. Churchill JA, Gammon GD. The effect of antihistaminic drugs on convulsive seizures. J. Am. Med. Assoc., 141, 18-21 (1949).
3. 1 antagonist, confirmed by the use of D-chlorpheniramine with monitoring electroencephalography. Methods Find. Exp. Clin. Pharmacol., 15, 183-188 (1993).
4. 1 antagonist. Neuropediatrics, 29, 320-321 (1998).
5. Takano T, Sakaue Y, Sokoda T, Sawai C, Akabori S, Maruo Y, Taga T, Ohno M, Takeuchi Y. Seizure susceptibility due to antihistamines in febrile seizures. Pediatr. Neurol., 42, 277-279 (2010).
6. 1-antagonists on electrically-induced seizure in developing mice. Psychopharmacology (Berl.), 112, 199-203 (1993).
7. 1 receptor antagonists on the anticonvulsant activity of antiepileptic drugs. Pol. J. Pharmacol., 53, 93-96 (2001).
8. 1 receptor antagonists on maximal electroshock seizure in infant rats. Biol. Pharm. Bull., 30, 477-480 (2007).
9. Scherkl R, Hashem A, Frey HH. Histamine in brain - its role in regulation of seizure susceptibility. Epilepsy Res., 10, 111-118 (1991).
10. 1 antagonists in amygdala-kindled rats. Brain Res., 991, 258-261 (2003).
11. Yawata I, Tanaka K, Nakagawa Y, Watanabe Y, Murashima YL, Nakano K. Role of histaminergic neurons in development of epileptic seizures in EL mice. Brain Res. Mol. Brain Res., 132, 13-17 (2004).
12. Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y. Properties of olopatadine hydrochloride, a new antiallergic/ antihistaminic drug. Arzneimittelforschung, 54, 809-829 (2004).
13. Kitano Y, Usui C, Takasuna K, Hirohashi M, Nomura M. Increasing-current electroshock seizure test: a new method for assessment of anti- and pro-convulsant activities of drugs in mice. J. Pharmacol. Toxicol. Methods, 35, 25-29 (1996).
14. Kaufman KR, Sachdeo RC. Caffeinated beverages and decreased seizure control. Seizure, 12, 519-521 (2003).
15. Mortelmans LJ, Van Loo M, De Cauwer HG, Merlevede K. Seizures and hyponatremia after excessive intake of diet coke. Eur. J. Emerg. Med., 15, 51 (2008).
16. Löscher W. Preclinical assessment of proconvulsant drug activity and its relevance for predicting adverse events in humans. Eur. J. Pharmacol., 610, 1-11 (2009).
17. Ribeiro JA, Sebastião AM. Caffeine and adenosine. J. Alzheimers Dis., 20 (Suppl. 1), S3-S15 (2010).
18. Kochanek PM, Vagni VA, Janesko KL, Washington CB, Crumrine PK, Garman RH, Jenkins LW, Clark RS, Homanics GE, Dixon CE, Schnermann J, Jackson EK. Adenosine A1 receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury. J. Cereb. Blood Flow Metab., 26, 565-575 (2006).
19. Francis A, Fochtmann L. Caffeine augmentation of electroconvulsive seizures. Psychopharmacology (Berl.), 115, 320-324 (1994).
20. Yokoyama H. The role of central histaminergic neuron system as an anticonvulsive mechanism in developing brain. Brain Dev., 23, 542-547 (2001).
21. McDonald JW, Johnston MV, Young AB. Differential ontogenic development of three receptors comprising the NMDA receptor/channel complex in the rat hippocampus. Exp. Neurol., 110, 237-247 (1990).
22. Insel TR, Miller LP, Gelhard RE. The ontogeny of excitatory amino acid receptors in rat forebrain - I. N-methyl-D-aspartate and quisqualate receptors. Neuroscience, 35, 31-43 (1990).
23. Caboche J, Mitrovic N, Le Saux F, Besson MJ, Sauter A, Maurin Y. Postnatal evolution of the γ-aminobutyric acid/benzodiazepine receptor complex in a model of inherited epilepsy: the quaking mouse. J. Neurochem., 52, 419-427 (1989).
24. A receptor subunits in seizure-prone and seizure-resistant rat models of temporal lobe epilepsy. J. Neurosci., 19, 4654-4661 (1999).
25. Velísek L, Velísková J, Ptachewich Y, Ortíz J, Shinnar S, MoshéSL. Age-dependent effects of γ-aminobutyric acid agents on flurothyl seizures. Epilepsia, 36, 636-643 (1995).
26. Kamei C, Kagawa Y, Izawa K, Yano H, Watanabe Y, Obara Y, Okada A, Kato A. Effect of levocetirizine on histamine-induced allergic models. Jpn. Pharmacol. Ther., 38, 409-417 (2010).
27. 1-antagonists. Drug Metab. Dispos., 31, 312-318 (2003).
28. 1-receptor antagonist. Drug Metab. Pharmacokinet., 23, 106-114 (2008).
29. 11C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. Br. J. Clin. Pharmacol., 61, 16-26 (2006).
30. 11C-doxepin positron emission tomography. J. Clin. Pharmacol., 44, 890-900 (2004).
31. Kubo N. [Social requirement of the antihistamines for Japanese pollinosis]. Nippon Yakurigaku Zasshi, 125, 279-284 (2005).
32. Smith SM, Gums JG. Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opin. Drug Metab. Toxicol., 5, 813-822 (2009).
33. Ishikura N, Kaneko K. Animal models for human epileptic disease. J. Clin. Experiment. Med., 193, 505-510 (2000).